Cellular immunity to CMV: Advancing to the next level

Pediatric Transplantation

Volumn 16, Issue 6, 2012, Pages 539-541

  Kumar, Deepali ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL DECISION MAKING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; SCREENING; SERODIAGNOSIS; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; TRANSPLANTATION;

EID: 84864629697     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01637.x     Document Type: Review

References (12)

1. Humar A, Snydman D,. AST infectious diseases community of practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009: 9 (Suppl 4): S78-S86.
2. Humar A, Lebranchu Y, Vincenti F, et al., The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010: 10: 1228-1237.
3. Lisboa LF, Preiksaitis JK, Humar A, Kumar D,. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011: 92: 1063-1068.
4. Humar A, Mazzulli T, Moussa G, et al., Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005: 5: 1065-1070. (Pubitemid 40571255)
5. Huskey J, Gralla J, Wiseman AC,. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011: 6: 423-429.
6. Kotton CN, Kumar D, Caliendo AM, et al., International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010: 89: 779-795.
7. Gandhi MK, Khanna R,. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004: 4: 725-738. (Pubitemid 39574344)
8. Walker S, Fazou C, Crough T, et al., Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007: 9: 165-170. (Pubitemid 46669086)
9. Kumar D, Chernenko S, Moussa G, et al., Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009: 9: 1214-1222.
10. Lisboa L, Kumar D, Wilson L, Humar A,. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with CMV viremia. Transplantation 2011: in press.
11. Patel M, Stefanidou M, Long C, et al., Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant 2012: 16: 18-28.
12. Sester U, Gärtner BC, Wilkens H, et al., Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005: 5: 1483-1489. (Pubitemid 40839442)